Literature DB >> 1671789

Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.

J P Baak1, D Chin, P J van Diest, R Ortiz, P Matze-Cok, S S Bacus.   

Abstract

Data regarding the prognostic value of HER-2/neu protein expression in breast cancer are conflicting, perhaps because of short follow-up and technical difficulties in the determination (the admixture of benign elements with the biochemical method and the subjectivity of the immunohistochemical assessment). Therefore, using digital image processing, we compared the correlation between and the prognostic value of (a) quantitative immunohistochemical HER-2/neu protein expression and (b) clinical, morphometric, and flow-cytometric DNA ploidy features; histologic grade; and biochemically assessed estrogen receptor content. Paraffin-embedded invasive breast Pancers of 82 patients with long-term follow-up were used. None of the patients had received adjuvant systemic therapy. HER-2/neu protein expression was significantly correlated with DNA index, lymph node status, and tumor size and, in the diploid tumors, was weakly correlated with the percentage of S-phase cells. Strong HER-2/neu protein expression was associated with a worse prognosis (although not significantly, p = 0.07). No differences were detected between cancers with or without axillary lymph node metastases. In survival analysis, the Multivariate Prognostic Index and the morphometric features were much stronger prognosticators than HER-2/neu protein overexpression, which, however, had additional prognostic value to that of many of the features analyzed, especially when more than 35% HER-2/neu protein levels (relative to the high expression SKBR3 cell line) were present. Combined diploidy and HER-2/neu protein content greater than 35% occurred in a small group of patients (n = 3), all of whom died. Likewise, in tetraploid cancers a combination of S-phase cells greater than or equal to 7% and HER-2/neu protein content greater than 35% was an ominous sign. In multivariate analysis, strong HER-2/neu protein overexpression was prognostically over-shadowed by the morphometric features. Nevertheless, it is important to further analyze the intriguing possibility of identifying a subgroup of breast cancer patients with a very poor outcome merely using cytometric analysis of paraffin-embedded material of the primary tumor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1671789

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  14 in total

Review 1.  Proliferation markers in tumours: interpretation and clinical value.

Authors:  P J van Diest; G Brugal; J P Baak
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

2.  A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group.

Authors:  P J van Diest; P van Dam; S C Henzen-Logmans; E Berns; M E van der Burg; J Green; I Vergote
Journal:  J Clin Pathol       Date:  1997-10       Impact factor: 3.411

3.  Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.

Authors:  D N Poller; M Galea; D Pearson; J Bell; W J Gullick; C W Elston; R W Blamey; I O Ellis
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

4.  ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors.

Authors:  A A Keshgegian
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

5.  Improved prognostication in small (pT1) breast cancers by image cytometry.

Authors:  M Aubele; G Auer; U Falkmer; A Voss; K Rodenacker; L E Rutquist; H Höfler
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

Review 6.  Prognostic value of proliferation in invasive breast cancer: a review.

Authors:  P J van Diest; E van der Wall; J P A Baak
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

Review 7.  DNA Cytometry Consensus Conference. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast.

Authors:  D W Hedley; G M Clark; C J Cornelisse; D Killander; T Kute; D Merkel
Journal:  Breast Cancer Res Treat       Date:  1993-10       Impact factor: 4.872

8.  Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer.

Authors:  J R Marks; P A Humphrey; K Wu; D Berry; N Bandarenko; B J Kerns; J D Iglehart
Journal:  Ann Surg       Date:  1994-04       Impact factor: 12.969

9.  Immunohistochemical overexpression of C-erbB-2 in the prognosis of breast cancer.

Authors:  A Tsuchiya; N Katagata; I Kimijima; R Abe
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

10.  Microfluidic processor allows rapid HER2 immunohistochemistry of breast carcinomas and significantly reduces ambiguous (2+) read-outs.

Authors:  Ata Tuna Ciftlik; Hans-Anton Lehr; Martin A M Gijs
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.